$ News

Sector Update: Health Care Stocks Rise Wednesday Afternoon

Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Here's Why Repare Therapeutics (NASDAQ:RPTX) Must Use Its Cash Wisely

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

Repare signs out-licensing deal with DCx Biotherapeutics

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Repare Therapeutics Announces Leadership Transitions

What Makes Repare Therapeutics (RPTX) a New Buy Stock

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results